1. Home
  2. MHN vs BNTC Comparison

MHN vs BNTC Comparison

Compare MHN & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MHN
  • BNTC
  • Stock Information
  • Founded
  • MHN 1997
  • BNTC 1995
  • Country
  • MHN United States
  • BNTC United States
  • Employees
  • MHN N/A
  • BNTC N/A
  • Industry
  • MHN Investment Bankers/Brokers/Service
  • BNTC Biotechnology: Pharmaceutical Preparations
  • Sector
  • MHN Finance
  • BNTC Health Care
  • Exchange
  • MHN Nasdaq
  • BNTC Nasdaq
  • Market Cap
  • MHN N/A
  • BNTC 352.5M
  • IPO Year
  • MHN N/A
  • BNTC N/A
  • Fundamental
  • Price
  • MHN $10.02
  • BNTC $13.74
  • Analyst Decision
  • MHN
  • BNTC Strong Buy
  • Analyst Count
  • MHN 0
  • BNTC 7
  • Target Price
  • MHN N/A
  • BNTC $24.71
  • AVG Volume (30 Days)
  • MHN 59.2K
  • BNTC 37.1K
  • Earning Date
  • MHN 01-01-0001
  • BNTC 05-16-2025
  • Dividend Yield
  • MHN 4.17%
  • BNTC N/A
  • EPS Growth
  • MHN N/A
  • BNTC N/A
  • EPS
  • MHN N/A
  • BNTC N/A
  • Revenue
  • MHN N/A
  • BNTC N/A
  • Revenue This Year
  • MHN N/A
  • BNTC N/A
  • Revenue Next Year
  • MHN N/A
  • BNTC N/A
  • P/E Ratio
  • MHN N/A
  • BNTC N/A
  • Revenue Growth
  • MHN N/A
  • BNTC N/A
  • 52 Week Low
  • MHN $8.69
  • BNTC $5.74
  • 52 Week High
  • MHN $10.81
  • BNTC $16.90
  • Technical
  • Relative Strength Index (RSI)
  • MHN 53.46
  • BNTC 51.06
  • Support Level
  • MHN $9.95
  • BNTC $13.10
  • Resistance Level
  • MHN $10.09
  • BNTC $15.69
  • Average True Range (ATR)
  • MHN 0.11
  • BNTC 0.73
  • MACD
  • MHN 0.04
  • BNTC -0.01
  • Stochastic Oscillator
  • MHN 87.27
  • BNTC 24.71

About BNTC Benitec Biopharma Inc.

Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.

Share on Social Networks: